Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Клинические рекомендации по профилактике и лечению тошноты и рвоты у больных, получающих химио- и лучевую противоопухолевую терапию
Клинические рекомендации по профилактике и лечению тошноты и рвоты у больных, получающих химио- и лучевую противоопухолевую терапию
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. An Oncol 2010; 21 (Suppl. 5): 232–43.
2. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 2.2010. http://www.nccn.org
3. Kris GM, Hesketh PJ, Somerfield MR et al. American society of clinical oncology guidline for antiemetics in oncology: update 2006. JCO 2006; 24 (18): 2932–47.
4. Andrews PL, Davis CJ. The mechanism of emesis induced by anti-cancer therapies. In: P.Andrews, G.Sangler (eds). Emesis in Anti-Cancer Therapy. London, Chapman and Hall 1993; p. 113–6.
5. Kaiser R, Brockmöller J. From symptom management to a rational antiemetic treatment approach for acute and vomiting. ASCO 2004; p. 573–8.
6. Kris MG. Delayed emesis following anticancer chemotherapy. Extended abstract book of Perugia Consensus conference on antiemetic therapy 1997; 65–70.
7. Roila F, Donati D, Tamberi S et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 1997; 10: 88–95.
8. Kris GM, Hesketh PJ, Herrstedt J et al. Consensus proposals for prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005; 13: 85–96.
9. Burish TG, Carey MP. Conditioned aversive respons in cancer chemotherapy patients: Theoretical and development analysis (review) 1986.
10. Aapro MS, Molassiotis A, Oliver I. Anticipatory nause and vomiting. Support Care Cancer 2005; 13: 117–21.
11. Morrow GR, Roscoe JA. Anticipatory nause and vomiting: models, mechanisms and management. Medical management of cancer treatment induced emesis, ed. Dicato. London, Dunitz 1998; p. 149–66.
12. Herrstedt J. New perspectives in antiemetic treatment. Support Care Cancer 1996; 4: 416–9.
13. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ. Enantioselective inhibition of apomorphine-induced emesis in ferret by neurokinin receptor antagonist CP-99, 994. Neuropharmacology 1994; 33: 259–60.
14. Van Belle SJP, Stamatakis L, Bleiberg Y et al. Dose-finding study of tropisrtron in cisplatin-induced nausea and vomiting. An Oncol 1994; 5: 821–5.
15. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in prevention of cisplatin-induced nause and vomiting. J Clin Oncol 1992; 10: 1969–75.
16. Seynaeve C, Schuller J, Buser K et al. Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicenter, double-blind, randomized, parallel group study. Br J Cancer 1992; 66: 192–7.
17. IGAR. Ondansetron versus granisetron, both combined with dexamethasone, in prevention of cisplatin-induced emesis. An Oncol 1995; 6: 805–10.
18. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in prophylaxis of cisplatin-induced acute emesis: a multicenter, double-blind, randomized, parallel-group study. Oncology 1994; 51: 113–8.
19. Tsavaris N, Kosmas M, Vadiaka CH et al. Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. J Exp Clin Cancer Res 2001; 20: 29–34.
20. Needles B, Miranda E, Rodrigues FMG et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in prevention of nausea and vomiting associated with higly emetogenic chemotherapy. Support Care Cancer 1999; 7: 347–53.
21. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204–10.
22. Riviere A. On behalf of Granisetron Study Group. Dose-finding study of granisetron in patients, receiving high-dose cisplatin chemotherapy. Br J Cancer 1994; 69: 967–71.
23. Navari R, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1241–8.
24. Hesketh P, Navari WH, Harker WG et al. A randomized double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of nausea and vomiting associated with high-dose cisplatin. J Clin Oncol 1994; 12: 596–601.
25. IGAR. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004; 22: 725–9.
26. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. An Oncol 2007; 18: 233–40.
27. Hesketh PJ, Grunberg SM, Graua RJ et al. The oral neurokinin-1 antagonist aprepitant for prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 2003; 21: 4112–9.
28. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Additional of neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090–8.
29. Pendergrass K, Hargreaves R, Petty KJ et al. APREPITANT. An oral NK1 antagonist for prevention of nausea and vomiting induced by highly emetogenic chemotherapy. Drugs of Today 2004; 40 (10): 853–63.
30. Needles B, Miranda E, Rodrigues FMG et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in prevention of nausea and vomiting associated with higly emetogenic chemotherapy. Support Care Cancer 1999; 7: 347–53.
31. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290–300.
32. Cocquyt V, Van Belle S, Reinhardt RR et al. L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-754, 030, compared to ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835–42.
33. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonist, L-758, 298 and MK-869. Cancer 2002; 94: 3032–41.
34. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by oral neurokinin-1 antagonist MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759–67.
35. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by the selective neurokinin-1-receptor antagonist, L-754, 030. Antiemetic Trials Group. N Engl J Med 1999; 340: 190–5.
36. de Witt R, Herrstedt J, Rapoport B et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III trials. Eur J Cancer 2004; 40: 403–10.
37. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. An Oncol 2006; 17: 1000–6.
38. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of Aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23 (12): 2822–30.
39. Rapoport B, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010; 18: 423–31.
40. Warr DG, Grunberg SM, Gralla RJ et al. The oral NK1 antagonist aprepitant for the prow Evention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo-controlled trials. Eur J Cancer 2005; 41: 1278–85.
2. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 2.2010. http://www.nccn.org
3. Kris GM, Hesketh PJ, Somerfield MR et al. American society of clinical oncology guidline for antiemetics in oncology: update 2006. JCO 2006; 24 (18): 2932–47.
4. Andrews PL, Davis CJ. The mechanism of emesis induced by anti-cancer therapies. In: P.Andrews, G.Sangler (eds). Emesis in Anti-Cancer Therapy. London, Chapman and Hall 1993; p. 113–6.
5. Kaiser R, Brockmöller J. From symptom management to a rational antiemetic treatment approach for acute and vomiting. ASCO 2004; p. 573–8.
6. Kris MG. Delayed emesis following anticancer chemotherapy. Extended abstract book of Perugia Consensus conference on antiemetic therapy 1997; 65–70.
7. Roila F, Donati D, Tamberi S et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 1997; 10: 88–95.
8. Kris GM, Hesketh PJ, Herrstedt J et al. Consensus proposals for prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005; 13: 85–96.
9. Burish TG, Carey MP. Conditioned aversive respons in cancer chemotherapy patients: Theoretical and development analysis (review) 1986.
10. Aapro MS, Molassiotis A, Oliver I. Anticipatory nause and vomiting. Support Care Cancer 2005; 13: 117–21.
11. Morrow GR, Roscoe JA. Anticipatory nause and vomiting: models, mechanisms and management. Medical management of cancer treatment induced emesis, ed. Dicato. London, Dunitz 1998; p. 149–66.
12. Herrstedt J. New perspectives in antiemetic treatment. Support Care Cancer 1996; 4: 416–9.
13. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ. Enantioselective inhibition of apomorphine-induced emesis in ferret by neurokinin receptor antagonist CP-99, 994. Neuropharmacology 1994; 33: 259–60.
14. Van Belle SJP, Stamatakis L, Bleiberg Y et al. Dose-finding study of tropisrtron in cisplatin-induced nausea and vomiting. An Oncol 1994; 5: 821–5.
15. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in prevention of cisplatin-induced nause and vomiting. J Clin Oncol 1992; 10: 1969–75.
16. Seynaeve C, Schuller J, Buser K et al. Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicenter, double-blind, randomized, parallel group study. Br J Cancer 1992; 66: 192–7.
17. IGAR. Ondansetron versus granisetron, both combined with dexamethasone, in prevention of cisplatin-induced emesis. An Oncol 1995; 6: 805–10.
18. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in prophylaxis of cisplatin-induced acute emesis: a multicenter, double-blind, randomized, parallel-group study. Oncology 1994; 51: 113–8.
19. Tsavaris N, Kosmas M, Vadiaka CH et al. Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. J Exp Clin Cancer Res 2001; 20: 29–34.
20. Needles B, Miranda E, Rodrigues FMG et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in prevention of nausea and vomiting associated with higly emetogenic chemotherapy. Support Care Cancer 1999; 7: 347–53.
21. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204–10.
22. Riviere A. On behalf of Granisetron Study Group. Dose-finding study of granisetron in patients, receiving high-dose cisplatin chemotherapy. Br J Cancer 1994; 69: 967–71.
23. Navari R, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1241–8.
24. Hesketh P, Navari WH, Harker WG et al. A randomized double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of nausea and vomiting associated with high-dose cisplatin. J Clin Oncol 1994; 12: 596–601.
25. IGAR. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004; 22: 725–9.
26. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. An Oncol 2007; 18: 233–40.
27. Hesketh PJ, Grunberg SM, Graua RJ et al. The oral neurokinin-1 antagonist aprepitant for prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 2003; 21: 4112–9.
28. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Additional of neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090–8.
29. Pendergrass K, Hargreaves R, Petty KJ et al. APREPITANT. An oral NK1 antagonist for prevention of nausea and vomiting induced by highly emetogenic chemotherapy. Drugs of Today 2004; 40 (10): 853–63.
30. Needles B, Miranda E, Rodrigues FMG et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in prevention of nausea and vomiting associated with higly emetogenic chemotherapy. Support Care Cancer 1999; 7: 347–53.
31. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290–300.
32. Cocquyt V, Van Belle S, Reinhardt RR et al. L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-754, 030, compared to ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835–42.
33. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonist, L-758, 298 and MK-869. Cancer 2002; 94: 3032–41.
34. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by oral neurokinin-1 antagonist MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759–67.
35. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by the selective neurokinin-1-receptor antagonist, L-754, 030. Antiemetic Trials Group. N Engl J Med 1999; 340: 190–5.
36. de Witt R, Herrstedt J, Rapoport B et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III trials. Eur J Cancer 2004; 40: 403–10.
37. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. An Oncol 2006; 17: 1000–6.
38. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of Aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23 (12): 2822–30.
39. Rapoport B, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010; 18: 423–31.
40. Warr DG, Grunberg SM, Gralla RJ et al. The oral NK1 antagonist aprepitant for the prow Evention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo-controlled trials. Eur J Cancer 2005; 41: 1278–85.
Авторы
И.В.Поддубная1, М.Р.Личиницер2, С.А.Тюляндин2, В.А.Горбунова2, В.В.Птушкин3, М.А.Абрамов2, Н.С.Бесова2, Л.В.Болотина4, И.С.Булавина5, О.А.Гладков6, И.С.Давиденко7, Л.Г.Жукова2, И.А.Королева8, В.О.Короленко9, Г.М.Манихас10,
А.В.Снеговой2, Ю.И.Тюкалов11, Р.Ш.Хасанов12, Л.Н.Шигапова12
1 Российская медицинская академия последипломного образования, Москва;
2 НИИ клинической онкологии ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва;
3 ФГУ ФНКЦ детской гематологии, онкологии и гематологии, Москва;
4 Московский научно-исследовательский онкологический институт им. П.А.Герцена, ФГУ;
5 Свердловский областной онкологический диспансер, Екатеринбург;
6 ГЛПУ Челябинский региональный клинический онкологический диспансер;
7 ГУЗ Краевой клинический онкологический диспансер ДЗКК, Краснодар;
8 ГУЗ Самарский областной клинический онкологический диспансер;
9 Государственный медицинский университет им. акад. И.П.Павлова, Санкт-Петербург;
10 Городской клинический онкологический диспансер, Санкт-Петербург;
11 НИИ онкологии Томского научного центра СО РАМН; 12ГУЗ Республиканский клинический онкологический диспансер МЗ РТ, Казань
1 Russian Medical Academy of Graduate Education, Moscow;
2 Research Institute of Clinical Oncology, N.N.Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow;
3 Federal Research and Clinical Center of Pediatric Hematology, Oncology, and Immunology, Moscow;
4 P.A.Herzen Moscow Oncology Research Institute;
5 Sverdlovsk Regional Oncology Dispensary;
6 Chelyabinsk Regional Clinical Oncology Dispensary;
7 Clinical Oncology Dispensary, Healthcare Department of the Krasnodar Territory, Krasnodar;
8 Samara Regional Clinical Oncology Dispensary;
9 Acad. I.P.Pavlov St.-Petersburg State Medical University;
10 St.-Petersburg Clinical Oncology Dispensary;
11 Oncology Research Institute, Tomsk Cancer Research Center, Siberian Branch, Russian Academy of Medical Sciences;
12 Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Tatarstan
А.В.Снеговой2, Ю.И.Тюкалов11, Р.Ш.Хасанов12, Л.Н.Шигапова12
1 Российская медицинская академия последипломного образования, Москва;
2 НИИ клинической онкологии ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва;
3 ФГУ ФНКЦ детской гематологии, онкологии и гематологии, Москва;
4 Московский научно-исследовательский онкологический институт им. П.А.Герцена, ФГУ;
5 Свердловский областной онкологический диспансер, Екатеринбург;
6 ГЛПУ Челябинский региональный клинический онкологический диспансер;
7 ГУЗ Краевой клинический онкологический диспансер ДЗКК, Краснодар;
8 ГУЗ Самарский областной клинический онкологический диспансер;
9 Государственный медицинский университет им. акад. И.П.Павлова, Санкт-Петербург;
10 Городской клинический онкологический диспансер, Санкт-Петербург;
11 НИИ онкологии Томского научного центра СО РАМН; 12ГУЗ Республиканский клинический онкологический диспансер МЗ РТ, Казань
________________________________________________
1 Russian Medical Academy of Graduate Education, Moscow;
2 Research Institute of Clinical Oncology, N.N.Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow;
3 Federal Research and Clinical Center of Pediatric Hematology, Oncology, and Immunology, Moscow;
4 P.A.Herzen Moscow Oncology Research Institute;
5 Sverdlovsk Regional Oncology Dispensary;
6 Chelyabinsk Regional Clinical Oncology Dispensary;
7 Clinical Oncology Dispensary, Healthcare Department of the Krasnodar Territory, Krasnodar;
8 Samara Regional Clinical Oncology Dispensary;
9 Acad. I.P.Pavlov St.-Petersburg State Medical University;
10 St.-Petersburg Clinical Oncology Dispensary;
11 Oncology Research Institute, Tomsk Cancer Research Center, Siberian Branch, Russian Academy of Medical Sciences;
12 Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Tatarstan
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.